Efficacy of sequential surgical resection for initial unresectable hepatocellular carcinoma after interventional therapy plus targeted immunotherapy

Duan Changhu; Duan Jianfeng; Wu Lin; Yang Fan; Liu Xiaochen

doi:10.3969/j.issn.1003-5591.2024.02.008

您当前的位置：

首页 >

文章列表页 >

Efficacy of sequential surgical resection for initial unresectable hepatocellular carcinoma after interventional therapy plus targeted immunotherapy

更新时间：2026-11-05

- Efficacy of sequential surgical resection for initial unresectable hepatocellular carcinoma after interventional therapy plus targeted immunotherapy
- J Abdominal Surg Vol. 37, Issue 2, Pages: 117-123(2024)
- 作者机构：
  
  西安交通大学医学院附属三二〇一医院肝胆胰脾外科，陕西汉中 723012
- 作者简介：
  
  Liu Xiaochen， Email： 675929952@qq.com
- 基金信息：
- DOI：10.3969/j.issn.1003-5591.2024.02.008
  CLC： R735.7
- Received：31 May 2023，
  
  Published：22 April 2024
- 稿件说明：
移动端阅览
段昌虎,段建峰,吴林等.初始不可切除肝癌行介入联合靶免转化治疗后序贯手术的疗效分析[J].腹部外科,2024,37(02):117-123.

Duan Changhu,Duan Jianfeng,Wu Lin,et al.Efficacy of sequential surgical resection for initial unresectable hepatocellular carcinoma after interventional therapy plus targeted immunotherapy[J].J Abdominal Surg,2024,37(02):117-123.
段昌虎,段建峰,吴林等.初始不可切除肝癌行介入联合靶免转化治疗后序贯手术的疗效分析[J].腹部外科,2024,37(02):117-123. DOI： 10.3969/j.issn.1003-5591.2024.02.008.

Duan Changhu,Duan Jianfeng,Wu Lin,et al.Efficacy of sequential surgical resection for initial unresectable hepatocellular carcinoma after interventional therapy plus targeted immunotherapy[J].J Abdominal Surg,2024,37(02):117-123. DOI： 10.3969/j.issn.1003-5591.2024.02.008.

摘要

目的

评估初始不可切除的晚期肝癌行局部介入治疗联合系统靶免转化治疗后序贯手术切除的临床疗效，分析其安全性、可行性。

方法

回顾性收集并分析西安交通大学医学院附属三二〇一医院自2021年6月至2023年4月期间收治的10例初始不可切除的晚期肝癌病人的临床资料。

结果

10例病人中，男性8例，女性2例，中位年龄55岁（33~72岁）；Child-Pugh分级标准A级6例，B级4例；中国肝癌分期Ⅱb期4例，Ⅲa期6例；转化治疗前肿瘤最大径为13 cm，甲胎蛋白

400 μg/L者7例，甲胎蛋白

400 μg/L者3例；合并门静脉癌栓者6例，无门静脉癌栓者4例；转化治疗方案：肝动脉灌注化疗栓塞+靶免治疗的有6例、肝动脉灌注化疗+靶免的有4例，转化治疗过程中合并高血压4例、乏力2例、腹泻1例；中位转化时间为4个月；转化结束后术前的中位甲胎蛋白水平为7.2 μg/L，肿瘤最大径缩小至8.8 cm，影像学评估完全缓解4例，部分缓解3例，疾病稳定3例；转化后行手术切除：3例行肝脏部分切除（2例右后叶切除，1例VI段切除），7例行半肝切除（2例左半肝切除，5例右半肝切除）；经腹腔镜手术7例，开腹手术3例。中位手术时间为40 min，中位出血量为400 mL，术后中位住院时间为8 d，中位拔除腹腔引流管时间为7 d。术后病理提示病理学完全缓解3例，病理学部分缓解有7例，微血管侵犯分级M

（无微血管侵犯）有8例，M

（≤5个微血管侵犯）有2例，术后切缘均为阴性。术后中位随访时间为8个月，1例复发，无病例死亡。

结论

部分初始不可切除的晚期肝癌病人，行介入联合靶免转化治疗后序贯手术切除，疗效确切，安全性可。

Abstract

Objective

To evaluate the clinical efficacy of sequential surgical resection for initial unresectable hepatocellular carcinoma （HCC） after interventional therapy plus targeted immunotherapy.

Methods

From June 2021 to April 2023， retrospective review was performed for the relevant clinical data from 10 patients of initial unresectable HCC .

Results

There were 8 males and 2 females with a median age of 55（33-72） years. Child Pugh grade was A （

=6） and B （

=4）. And China Liver Cancer （CNLC） stage was Ⅱb （

=4） and Ⅲa （

=6）. Portal vein cancer thrombus was present （

=6） or absent （

=4）. Maximal tumor diameter prior to transformation therapy was 13 cm. The pre-treatment level of alpha feto-protein （AFP） was

400 μg/L （

=7） and

400 μg/L （

=3）. Conversion treatment protocol was transcatheter arterial chemoembolization （TACE） plus targeted immunotherapy （

=6） and hepatic artery infusion chemotherapy （HAIC） plus targeted immunotherapy （

=4）. There were hypertension （

=4）， fatigue （

=2） and diarrhea （

=1） during treatment. Median conversion time was 4 months. Median preoperative level of AFP after conversion therapy was 7.2 μg/L and maximal preoperative diameter of tumor after conversion therapy 8.8 cm. Preoperative imaging assessment of outcomes was complete remission （CR，

=4）， partial remission （PR，

=3） and stable disease （SD，

=3）. After therapy， the procedures included partial hepatectomy （

=3）， semi-hepatic resection （

=7）， laparoscopy （

=7） and open surgery （

=3）. Median surgical time was 240 min， median intraoperative volume of blood loss 400 mL， median postoperative hospital stay 8 days and median postoperative drainage tube removal time 7 days. Postoperative pathological

results were pCR （

=3） and pPR （

=7）. MVI grade was M

（

=8） and M

（

=2）. There was no positive case of resection margin. There were postoperative ascites （

=1） and bile leakage （

=1）. No obvious postoperative complications occurred. During a median postoperative follow-up period of 8 months， one case recurred and there was no death.

Conclusion

For initial unresectable HCC， sequential surgical resection along with interventional therapy plus targeted immunotherapy is both effective and safe.

关键词

Keywords

references

Sung H ， Ferlay J ， Siegel RL ， et al . Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries ［J］. CA Cancer J Clin ， 2021 ， 71 （ 3 ）： 209 - 249 . DOI： 10.3322/caac.21660 http://dx.doi.org/10.3322/caac.21660 .

Llovet JM ， Kelley RK ， Villanueva A ， et al . Hepatocellular carcinoma ［J］. Nat Rev Dis Primers ， 2021 ， 7 （ 1 ）： 6 . DOI： 10.1038/s41572-020-00240-3 http://dx.doi.org/10.1038/s41572-020-00240-3 .

袁声贤，周伟平 . 肝细胞癌降期转化的治疗策略［J］. 临床肝胆病杂志， 2020 ， 36 （ 2 ）： 252 - 257 . DOI： 10.3969/j.issn.1001-5256.2020.02.002 http://dx.doi.org/10.3969/j.issn.1001-5256.2020.02.002 .

中国抗癌协会肝癌专业委员会转化治疗协作组 . 肝癌转化治疗中国专家共识（2021版）［J］. 中华消化外科杂志， 2021 ， 20 （ 6 ）： 600 - 616 . DOI： 10.3760/cma.j.cn115610-20210512-00223 http://dx.doi.org/10.3760/cma.j.cn115610-20210512-00223 .

中华人民共和国国家卫生健康委员会医政医管局 . 原发性肝癌诊疗指南（2022年版）［J］. 中华消化外科杂志， 2022 ， 21 （ 2 ）： 143 - 168 . DOI： 10.3760/cma.j.cn115610-20220124-00053 http://dx.doi.org/10.3760/cma.j.cn115610-20220124-00053 .

中华预防医学会肝胆胰疾病预防与控制专业委员会，中国抗癌协会肝癌专业委员会，北京医学会外科学分会肝脏学组，等 . 基于免疫联合靶向方案的晚期肝细胞癌转化治疗中国专家共识（2021版）［J］. 中华肝胆外科杂志， 2021 ， 27 （ 4 ）： 241 - 251 . DOI： 10.3760/cma.j.cn113884-20210415-00138 http://dx.doi.org/10.3760/cma.j.cn113884-20210415-00138 .

He MK ， Le Y ， Li QJ ， et al . Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma：a prospective non-randomized study ［J］. Chin J Cancer ， 2017 ， 36 （ 1 ）： 83 . DOI： 10.1186/s40880-017-0251-2 http://dx.doi.org/10.1186/s40880-017-0251-2 .

Park JW ， Chen MS ， Colombo M ， et al . Global patterns of hepatocellular carcinoma management from diagnosis to death：the BRIDGE Study ［J］. Liver Int ， 2015 ， 35 （ 9 ）： 2155 - 2166 . DOI： 10.1111/liv.12818 http://dx.doi.org/10.1111/liv.12818 .

黄傲，郭德镇，周俭 . 靶向和免疫治疗时代的肝癌转化治疗［J］. 实用肿瘤杂志， 2023 ， 38 （ 2 ）： 101 - 104 . DOI： 10.13267/j.cnki.syzlzz.2023.017 http://dx.doi.org/10.13267/j.cnki.syzlzz.2023.017 .

Lyu N ， Kong YN ， Mu LW ， et al . Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs .sorafenib for advanced hepatocellular carcinoma ［J］. J Hepatol ， 2018 ， 69 （ 1 ）： 60 - 69 . DOI： 10.1016/j.jhep.2018.02.008 http://dx.doi.org/10.1016/j.jhep.2018.02.008 .

Lee SW ， Lee TY ， Peng YC ， et al . The therapeutic benefits of combined sorafenib and transarterial chemoembolization for advanced hepatocellular carcinoma ［J］. J Dig Dis ， 2020 ， 21 （ 5 ）： 287 - 292 . DOI： 10.1111/1751-2980.12866 http://dx.doi.org/10.1111/1751-2980.12866 .

张恒，江斌，王健，等 . 阿帕替尼联合肝动脉化疗栓塞术治疗BCLC B/C期肝癌的临床疗效［J］. 腹部外科， 2021 ， 34 （ 2 ）： 138 - 143 . DOI： 10.3969/j.issn.1003-5591.2021.02.013 http://dx.doi.org/10.3969/j.issn.1003-5591.2021.02.013 .

孙惠川 . 不可切除和中晚期肝癌的转化切除［J］. 腹部外科， 2021 ， 34 （ 2 ）： 85 - 87 . DOI： 10.3969/j.issn.1003-5591.2021.02.001 http://dx.doi.org/10.3969/j.issn.1003-5591.2021.02.001 .

Wang JL ， Zheng ZK ， Wu TQ ， et al . Hepatic arterial infusion chemotherapy as a timing strategy for conversion surgery to treat hepatocellular carcinoma：a single-center real-world study ［J］. J Hepatocell Carcinoma ， 2022 ， 9 ： 999 - 1010 . DOI： 10.2147/JHC.S379326 http://dx.doi.org/10.2147/JHC.S379326 .

He MK ， Liang RB ， Zhao Y ， et al . Lenvatinib，toripalimab，plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma ［J］. Ther Adv Med Oncol ， 2021 ， 13 ： 17588359211002720 . DOI： 10.1177/1758835921100-2720 http://dx.doi.org/10.1177/1758835921100-2720 .

Cho JY ， Han HS ， Choi Y ， et al . Association of remnant liver ischemia with early recurrence and poor survival after liver resection in patients with hepatocellular carcinoma ［J］. JAMA Surg ， 2017 ， 152 （ 4 ）： 386 - 392 . DOI： 10.1001/jamasurg.2016.5040 http://dx.doi.org/10.1001/jamasurg.2016.5040 .

李豪，陈国勇，魏思东，等 . 原发性肝癌患者肝切除术后复发影响因素分析［J］. 中国肝脏病杂志（电子版）， 2019 ， 11 （ 3 ）： 69 - 74 . DOI： 10.3969/j.issn.1674-7380.2019.03.013 http://dx.doi.org/10.3969/j.issn.1674-7380.2019.03.013 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Current status and analysis of combined therapy based on the hepatic arterial infusion chemotherapy for middle-stage and advanced hepatocellular carcinoma

Perioperative immunotherapy for biliary tract cancer： current status and future directions

Current status and perspectives on conversion therapy for hepatocellular carcinoma in the era of targeted immunotherapy

Clinical decision on surgical resection for patients with complete response after conversion therapy for hepatocellular carcinoma： controversy and consensus

Signaling pathways for early recurrence after hepatectomy for hepatocellular carcinoma

Related Author

Wang Zhengwen

Xu Shengjiang

Wang Xianzheng

Pan Caiyan

Tang Zhe

Liu Zhaochen

Gao Zhiqiang

Li Xin

Related Institution

The First Clinical College of Hainan Medical University

Department of Hepatobiliary and Pancreatic Surgery，Hainan Cancer Hospital（The Affiliated Cancer Hospital of Hainan Medical University）；Hainan Clinical Medical Research Center of Liver Disease and Liver Critical Illness

Department of Hepatobiliary and Pancreatic Surgery， the First Affiliated Hospital of Zhengzhou University

Ward I， Department of Hepatic-Biliary-Pancreatic Surgery， the Central Hospital of Wuhan， Tongji Medical College， Huazhong University of Science and Technology

Department of Hepatobiliary Surgery，Sun Yat-sen Memorial Hospital，Sun Yat-sen University

AI问答

⁰